The HOPE Study: putting it's experience into clinical practice


Cite item

Full Text

Abstract

We discuss the results of the HOPE study showing significant prognosis improvement in high-risk patients treated with ramipril, and important implications of this finding for real clinical practice

References

  1. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J. Hypertens. 2007;25:1105-1187.
  2. Российское медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008.
  3. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Качество профилактики и лечения сердечно-сосудистых заболеваний и их осложнений у больных сахарным диабетом типа 2 в амбулаторных условиях. Кардиоваскулярная терапия и профилактика 2008;7(7):9-14.
  4. Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается // Терапевтический архив. 2006. № 9. С. 5-12.
  5. Brown B., Hall A. Renin-angiotensin system: the weight of evidence. Am. J. Hypertens. 2005;18:127S-133S.
  6. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can. J. Cardiol. 1996;12:127-37.
  7. The Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000;342:145-53.
  8. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-59.
  9. Mann J.F., Gerstein H.C., Yi Q.L., et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J. Am. Soc. Nephrol. 2003;14(3):641-47.
  10. Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104(14):1615-21.
  11. Lonn E., Shaikholeslami R., Yi Q., et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J. Am. Coll. Cardiol. 2004;43(12):2200-06.
  12. Lonn E., Mathew J., Pogue J., et al.; Heart Outcomes Prevention Evaluation Study Investigators. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur. J. Cardiovasc. Prev. Rehabil. 2003;10(6):420-28.
  13. Sumner G., Salehian O., Yi Q. et al.; HOPE Investigators. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. J. Cardiovasc. Electrophysiol. 2009;20(7):781-87.
  14. Mann J.F., Yi Q.L., Sleight P. et al. J; HOPE Investigators. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin. Nephrol. 2005;63(3):181-87.
  15. Teo K.K., Mitchell L.B., Pogue J. et al.; HOPE Investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation. 2004; 110(11): 1413-17.
  16. Arnold J.M., Yusuf S., Young J. et al.; HOPE Investigators. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107(9):1284-90.
  17. Blankenberg S., McQueen M.J., Smieja M., et al.; HOPE Study Investigators. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114(3):201-08.
  18. Dagenais G.R., Yusuf S., Bourassa M.G., et al.; HOPE Investigators. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001;104(5):522-26.
  19. Bosch J., Yusuf S., Pogue J., et al. Use of ramipril in preventing stroke: double blind randomised trial. B.M.J. 2002;324:699-702.
  20. Ostergren J., Sleight P., Dagenais G., et al.; HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur. Heart J. 2004;25(1):17-24.
  21. Lonn E., Roccaforte R., Yi Q., et al.; HOPE Investigators. Effect of long-term therapy with ramipril in high-risk women. J. Am. Coll. Cardiol. 2002;40(4):693-702.
  22. Carroll C.A., Coen M.M., Rymer M.M. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study. Clin. Ther. 2003;25(4):1248-61.
  23. Hemels M.E., Bennett H.A., Bonari L., et al. HOPE study impact on ACE inhibitors use. Ann. Pharmacother. 2003;37(5):640-45.
  24. Yusuf S., Dagenais G., Pogue J., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000;342(3):154-60.
  25. Lonn E., Yusuf S., Hoogwerf B., et al.; HOPE Study; MICRO-HOPE Study. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002;25(11):1919-27.
  26. Lonn E., Bosch J., Yusuf S., et al.; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. J.A.M.A. 2005;293(11):1338-47.
  27. Lonn E., Yusuf S., Dzavik V., et al.; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103(7):919-925.
  28. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008;358(15):1547-59.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies